Please login to the form below

Not currently logged in
Email:
Password:

Medtronic heart devices approved

The US Food and Drug Administration has approved a new family of implantable cardiac devices from Medtronic that are intended to reduce the number of inappropriate therapeutic shocks that are delivered

The US Food and Drug Administration has approved a new family of implantable cardiac devices from Medtronic that are intended to improve patients' quality of life by significantly reducing the number of inappropriate therapeutic shocks that are delivered.

The new Protecta portfolio of products, which will begin shipments immediately, includes implantable cardioverter-defibrillators (ICDs) and cardiac resynchronisation therapy-defibrillators (CRT-Ds) that use the company's SmartShock Technology, which is based on six algorithms that recognise life-threatening arrhythmias and deliver therapeutic shocks only when appropriate.

A virtual study conducted by Medtronic based on a statistical model found that the technology results in 98 per cent of patients being free of inappropriate shocks one year after implant and 92 per cent being free of inappropriate shocks five years after implant.

Currently, up to one in five patients with implantable defibrillators may experience inappropriate shocks in response to a benign arrhythmia or electrical noise sensed by the device, according to the company.

29th March 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...

Infographics